Steven Naymagon, MD
Gastroenterology · New York, NYNPI 1730349218
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Takeda Pharmaceuticals U.S.A., Inc. accounts for 73.3% of it on its own, with 37 other manufacturers making up the rest. 2025 is the largest year on record at $46,645, more than ten times the $2,385 reported in 2019. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,456 payments — averaging $59.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$63K
- AbbVie$5K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Johnson & Johnson$3K
- Bristol Myers Squibb$2K
- QOL Medical, LLC$1K
- plus $8K from 32 others
What the payments were for
- Speaking & faculty fees$49,05957%
- Travel & lodging$10,33812%
- Food & beverage$26,85631%
- Education$2490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,502 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 19 | $453,443 |
| RemicadeInfliximab | 14 | $112,643 |
| RinvoqUpadacitinib | 12 | $73,164 |
| DificidFidaxomicin | 11 | $52,301 |
| Octreotide Acetate | 14 | $39,844 |
| LinzessLinaclotide | 37 | $32,019 |
| ZenpepLipase/Protease/Amylase | 11 | $28,252 |
| Yusimry(Cf) PenAdalimumab-Aqvh | 11 | $19,360 |
| Mesalamine | 45 | $19,056 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 60 | $10,173 |
| Mesalamine ErMesalamine | 12 | $10,126 |
| Famotidine | 159 | $2,808 |
| Sucralfate | 16 | $2,506 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 15 | $2,396 |
| Budesonide EcBudesonide | 12 | $2,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Remicade | $3,219 | $566,08633 claims |
| AbbVieRinvoq, Linzess | $5,199 | $105,18349 claims |
| MerckDificid | $946 | $52,30111 claims |
| Aimmune Therapeutics, Inc.Zenpep | $273 | $28,25211 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $430 | $10,17360 claims |
| Braintree Laboratories, Inc.Sutab | $65 | $2,39615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in New York
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
- Caterina Oneto ArayaNew York$610K
- Dana LukinNew York$491K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.